You are viewing the site in preview mode

Skip to main content

Advertisement

Table 1 Baseline Demographics, WHO treatment stage (T stage), and WHO immunologic classification of Standardized Pediatric Expedited Encounters for ART Drugs Initiative (SPEEDI) patients (n = 1164)

From: The Standardized Pediatric Expedited Encounters for ART Drugs Initiative (SPEEDI): description and evaluation of an innovative pediatric, adolescent, and young adult antiretroviral service delivery model in Tanzania

Characteristic SPEEDI Patients (n = 1164)
% Females (n) 52.0% (605/1164)
Mean age (range) 11.8 years (1.2–25.5)
Age categories
  < 5yo 142 (12.2%)
 5-9yo 322 (27.7%)
 10-14yo 353 (30.3%)
 15-18yo 251 (21.6%)
  > 19yo 96 (8.2%)
Mean time on ART (range) 32 months (4–130 months)
WHO T-stages (%, n) T1: 95% (1106/1164) N/A*: 5.0% (58/1164)
WHO Immunological classification of HIV-associated immunodeficiency [16] (%, n) None: 68.7% (793/1155) Mild: 14.8% (171/1155) Advanced: 10.0% (115/1155) Severe: 6.6% (76/1155)
  1. *“N/A” was assigned as a T-stage for patients on ART < 6 months. Those on ART for ≥6 months were assigned a T-stage